CoChat

T-cell responses against CD19+ pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80/CD86 on leukemic blasts

Open access
Feucht, Judith, Kayser, Simone, Gorodezki, David, Hamieh, Mohamad, Döring, Michaela, Blaeschke, Franziska, Schlegel, Patrick, Bösmüller, Hans, Quintanilla-Fend, Leticia, Ebinger, Martin, Lang, Peter, Handgretinger, Rupert, Feuchtinger, Tobias · 2016 · Oncotarget
Cited by 171

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

// Judith Feucht 1, 2 , Simone Kayser 1 , David Gorodezki 1 , Mohamad Hamieh 2 , Michaela Döring 1, 3 , Franziska Blaeschke 3 , Patrick Schlegel 1 , Hans Bösmüller 4 , Leticia Quintanilla-Fend 4 , Martin Ebinger 1 , Peter Lang 1 , Rupert Handgretinger 1 , Tobias Feuchtinger 1, 3 1 Department of General Pediatrics, Hematology and Oncology, Children’s University Hospital Tübingen, Tübingen, Germany 2 Memorial Sloan Kettering Cancer Center, Center for Cell Engineering, New York, NY, USA 3 Dr. von Hauner Children’s Hospital, Ludwig Maximilians University Munich, Munich, Germany 4 Institute of Pathology, University Hospital Tübingen, Tübingen, Germany Correspondence to: Tobias Feuchtinger, email: tobias.feuchtinger@med.uni-muenchen.de Keywords: pediatric acute lymphoblastic leukemia, T cells, immune checkpoints, PD-L1, CD80/86, blinatumomab Received: April 18, 2016 Accepted: September 02, 2016 Published: September 30, 2016 ABSTRACT T-cell immunotherapies are promising options in relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL). We investigated the effect of co-signaling molecules on T-cell attack against leukemia mediated by CD19/CD3-bispecific T-cell engager. Primary CD19 + ALL blasts (n≥10) and physiologic CD19 + CD10 + bone marrow precursors were screened for 20 co-signaling molecules. PD-L1, PD-1, LAG-3, CD40, CD86, CD27, CD70 and HVEM revealed different stimulatory and inhibitory profiles of pediatric ALL compared to physiologic cells, with PD-L1 and CD86 as most prominent inhibitory and stimulatory markers. PD-L1 was increased in relapsed ALL patients (n=11) and in ALLs refractory to Blinatumomab (n=5). Exhaustion markers (PD-1, TIM-3) were significantly higher on patients’ T cells compared to physiologic controls. T-cell proliferation and effector function was target-cell dependent and correlated to expression of co-signaling molecules. Blockade of inhibitory PD-1-PD-L and CTLA-4-CD80/86 pathways enhanced T-cell function whereas blockade of co-stimulatory CD28-CD80/86 interaction significantly reduced T-cell function. Combination of Blinatumomab and anti-PD-1 antibody was feasible and induced an anti-leukemic in vivo response in a 12-year-old patient with refractory ALL. In conclusion, ALL cells actively regulate T-cell function by expression of co-signaling molecules and modify efficacy of therapeutic T-cell attack against ALL. Inhibitory interactions of leukemia-induced checkpoint molecules can guide future T-cell therapies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.12357

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 171

Metadata

Authors
Feucht, J., Kayser, S., Gorodezki, D., Hamieh, M., Döring, M., Blaeschke, F., Schlegel, P., Bösmüller, H., Quintanilla-Fend, L., Ebinger, M., Lang, P., Handgretinger, R., & Feuchtinger, T.
Venue
Oncotarget
Published
2016-09-30
Volume
7
Issue
47
Pages
76902-76919
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2527615464
Cited by
171
References
6
FWCI
7.11
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: T-cell responses against CD19+ pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80/CD86 on leukemic blasts. https://app.cochat.ai/papers/10.18632/oncotarget.12357
The paper
Feucht, J., Kayser, S., Gorodezki, D., Hamieh, M., Döring, M., Blaeschke, F., Schlegel, P., Bösmüller, H., Quintanilla-Fend, L., Ebinger, M., Lang, P., Handgretinger, R., & Feuchtinger, T. (2016). T-cell responses against CD19+ pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80/CD86 on leukemic blasts. Oncotarget. https://doi.org/10.18632/oncotarget.12357

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.